ArticleFrontiers in public health2025
Systematic analysis of gout burden among young adults in China from 1990 to 2021: findings from the global burden of disease study 2021.
Article in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Epidemiological trends and burden of gout in China and the European Union: a GBD 2023 and Mendelian randomization study.Clinical rheumatology · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Gout, a disabling inflammatory arthritis, closely linked to metabolic diseases such as hyperuricemia, obesity, hypertension, and diabetes, is increasingly prevalent among young adults in China. Understanding the burden of gout and its risk factors among young adults in China is crucial for developing effective prevention and management strategies. Methods: We analyzed data from the Global Burden of Disease Study 2021 (GBD 2021) on gout prevalence, incidence, and disability-adjusted life years (DALYs) among young adults (individuals aged 15-39 years) in China from 1990 to 2021. Joinpoint regression and the AutoRegressive Integrated Moving Average (ARIMA) model were used to assess trends and predict future burden. Summary exposure values (SEVs) were used to evaluate risk factors. Results: The study found that the burden of gout among young adults in China is significantly higher than the global average and shows a continuous upward trend. Males have a higher burden and age-standardized rates on all indicators, including prevalence, incidence, and DALYs. Joinpoint regression analysis revealed that from 1990 to 2021, the burden of gout has experienced rapid growth, stabilization, and a resurgence of acceleration since 2019. ARIMA model projects different epidemiological trends for gout across 2022-2036, with age-standardized prevalence rate (ASPR) and age-standardized incidence rate (ASIR) declining while age-standardized DALYs rate (ASDR) gradually rise. Gender-specific disparities persist. Females demonstrate a predictable rise in ASPR, ASIR and ASDR. Despite males facing higher baseline burdens and accelerating ASDR growth, their ASPR and ASIR exhibit downward trends. A significant rise in gout risk factors among Chinese aged 15-39 from 1990 to 2021 highlights the need to face the upcoming gout burden and carry out targeted measures for this population. Conclusion: The rising burden of gout among young Chinese adults demands immediate gender- and age-specific public health action. Targeted interventions focusing on modifiable risk factors such as dietary habits and lifestyle are crucial to reduce the impact of gout on young adults.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.